A carregar...
Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
No effective targeted therapies exist for cancers with somatic KRAS mutations. Here we develop a synthetic lethal chemical screen in isogenic KRAS-mutant and wild-type cells to identify clinical drug pairs. Our results show that dual inhibition of polo-like kinase 1 and RhoA/Rho kinase (ROCK) leads...
Na minha lista:
| Publicado no: | Nat Commun |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4873974/ https://ncbi.nlm.nih.gov/pubmed/27193833 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms11363 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|